Geider takes reins at ICC Lowe Pace

Share this article:
Gregg Geider
Gregg Geider

Gregg Geider, who headed up the Januvia diabetes account while at Omnicom's Harrison & Star, has joined IPG's ICC Lowe Pace as its new managing director, effective this month. He replaces Margaret Anne Ingram, SVP, management supervisor, who moves to the role of new business director.

While this is Geider's first role helming an agency, he comes to the full-service shop after high-profile work for some well-known brands. Most recently he led the professional brief for Merck's Januvia diabetes pill, which H&S had picked up in an agency consolidation in 2012. For several years, he also led global messaging for AbbVie's autoimmune blockbuster Humira, also at NYC-based H&S.

“[Gregg's] used to bringing resources together, and that's what I want Pace clients to expect moving forward,” said Steve Viviano, CEO of ICC Lowe. 

“I'm uniquely positioned to look into…what our clients and brands need and leverage those resources as necessary,” said Geider.

ICC Lowe Pace is one of two US-based conflict shops in the ICC Lowe network, the other being ICC Lowe Trio. It was rebranded to ICC Lowe Pace three years ago along with the rest of the ICC shops after Interpublic Group, ICC's parent, allowed Viviano to take over and grow healthcare within the holding company's Lowe & Partners network. 

Geider adds to a deep bench at the agency, which touts its depth and senior-level talent, a growing client base, but with a smaller agency's touch.

“The positioning for the office is ‘the boutique with access to the larger resources of ICC Lowe,' and we think that will go a long way for us,” said Viviano, citing the shop's DTC work as well as high-science accounts. “Gregg's focus now is on existing clients and helping them solve their challenges.”

Share this article:
You must be a registered member of MMM to post a comment.

Next Article in Channel


Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Channel

Five things for pharma marketers to know: Monday, September 15

Five things for pharma marketers to know: ...

Pharma has sought 76 meetings with FDA over biosimilars; Gilead licenses Sovaldi to India generic drugmakers; Pfizer and Ranbaxy Lipitor lawsuit dismissed.

Liraglutide, aiming for new indication, gets new name

Liraglutide, aiming for new indication, gets new name

Why Novo Nordisk is choosing not to leverage Victoza's brand equity as it seeks a weight-loss indication for liraglutide.

Five things for pharma marketers to know: Friday, September 12

Five things for pharma marketers to know: Friday, ...

An FDA panel voted in favor of liraglutide for weight loss; Allergan investors backing an attempted takeover of the firm crossed a critical threshold; and 100 million health wearables are ...